Regions showing significantly differences between RS and CLL phase, CLL phase and CLL-U, and RS and de novo DLBCL
| Lesion . | Start* . | Size, Kb* . | RS, % . | % . | Candidate genes . | No. genes† . | P . |
|---|---|---|---|---|---|---|---|
| RS and CLL phase | |||||||
| +1q32.1 | 2.02E+08 | 3.53E+03 | 15 | 0 | MDM4 | 60 | .034 |
| +1q25.3 | 1.81E+08 | 1.76E+03 | 15 | 0 | 11 | .034 | |
| +3q21.1-q29 | 1.23E+08 | 7.44E+04 | 13 | 0 | >100 | .046 | |
| +3q25.2-q26.31 | 1.54E+08 | 2.13E+04 | 13 | 0 | 92 | .046 | |
| −1q42.12-q42.3 | 2.26E+08 | 1.03E+04 | 15 | 0 | 90 | .034 | |
| −1p36.33-p36.23 | 6.17E+04 | 8.75E+03 | 15 | 0 | TNFRSF14, TP73 | >100 | .034 |
| −9p21.3 | 2.13E+07 | 1.30E+03 | 22 | 0 | CDKN2A | 17 | .005 |
| −19p13.2-p13.11 | 1.29E+07 | 6.17E+03 | 15 | 0 | TNFSF9 | >100 | .034 |
| CLL phase and CLL-U | |||||||
| +2p25.3-p13.1 | 1.28E+04 | 7.40E+04 | 14 | 3 | REL, MYCN | >100 | .00432 |
| −8p23.3-p12 | 4.64E+04 | 3.45E+04 | 11 | 3 | >100 | .0302 | |
| −13q14.2-q14.3 | 5.05E+07 | 1.11E+03 | 32 | 53 | DLEU2/MIR15A/MIR16 | 12 | .034 |
| −15q15.1 | 4.01E+07 | 2.29E+03 | 14 | 3 | MGA | 55 | .0023 |
| −17p13.3-p11.2 | 5.26E+02 | 2.02E+04 | 32 | 6 | TP53 | >100 | <.00001 |
| −15q15.1 (homozygous loss) | 5.26E+02 | 2.02E+04 | 4 | 0.3 | MGA | 17 | .03025 |
| RS and de novo DLBCL | |||||||
| +1q32.1 | 2.02E+08 | 3.37E+03 | 15 | 28 | MDM4 | 57 | .0311 |
| −1p36.33-p36.31 | 6.17E+04 | 6.56E+03 | 15 | 28 | TNFRSF14, TP73 | >100 | .0196 |
| +2p16.1-p15 | 6.07E+07 | 2.38E+03 | 10 | 22 | REL | 19 | .0269 |
| +3q27-q29 | 1.88E+08 | 1.03E+04 | 13 | 28 | 81 | .0087 | |
| +5p15-q15 | 1.55E+04 | 9.55E+04 | 2 | 18 | >100 | .002 | |
| +6p25.3-p12.1 | 1.50E+05 | 5.38E+04 | 3 | 16 | >100 | .016 | |
| −6q23.3 | 1.37E+08 | 1.73E+03 | 9 | 38 | TNFAIP3 | 12 | .00003 |
| −6q16.3-q21 | 1.01E+08 | 6.50E+03 | 10 | 35 | PRDM1 | 17 | .00049 |
| +7 | 4.33E+04 | 1.59E+05 | 5 | 34 | >100 | .00002 | |
| −7q31.31-q36.3 | 1.18E+08 | 4.10E+04 | 13 | 3 | >100 | .017 | |
| +9q31.1-q34.11 | 1.08E+08 | 2.29E+04 | 4 | 12 | >100 | .023 | |
| −11q22.3 | 1.08E+08 | 4.97E+03 | 13 | 2 | ATM | 1 | .0046 |
| +12 | 1.00E+00 | 1.34E+08 | 27 | 17 | >100 | .046 | |
| −13q14.3 | 5.05E+07 | 1.10E+06 | 28 | 12 | DLEU2/MIR15A/MIR16 | 12 | .0075 |
| −14q24.1-q32.33 | 6.93E+07 | 3.69E+04 | 15 | 3 | TRAF3 | >100 | .0062 |
| −15q21.1-q21.1 | 4.11E+07 | 3.93E+03 | 7 | 31 | B2M, MGA | 78 | .0017 |
| +18 | 1.15E+04 | 7.80E+07 | 14 | 32 | BCL2, MALT1, NFATC1 | >100 | .011 |
| +20 | 6.13E+04 | 6.29E+04 | 0 | 13 | >100 | .0033 | |
| +21p11.2-q22.3 | 1.07E+07 | 3.74E+07 | 3 | 17 | >100 | .0090 |
| Lesion . | Start* . | Size, Kb* . | RS, % . | % . | Candidate genes . | No. genes† . | P . |
|---|---|---|---|---|---|---|---|
| RS and CLL phase | |||||||
| +1q32.1 | 2.02E+08 | 3.53E+03 | 15 | 0 | MDM4 | 60 | .034 |
| +1q25.3 | 1.81E+08 | 1.76E+03 | 15 | 0 | 11 | .034 | |
| +3q21.1-q29 | 1.23E+08 | 7.44E+04 | 13 | 0 | >100 | .046 | |
| +3q25.2-q26.31 | 1.54E+08 | 2.13E+04 | 13 | 0 | 92 | .046 | |
| −1q42.12-q42.3 | 2.26E+08 | 1.03E+04 | 15 | 0 | 90 | .034 | |
| −1p36.33-p36.23 | 6.17E+04 | 8.75E+03 | 15 | 0 | TNFRSF14, TP73 | >100 | .034 |
| −9p21.3 | 2.13E+07 | 1.30E+03 | 22 | 0 | CDKN2A | 17 | .005 |
| −19p13.2-p13.11 | 1.29E+07 | 6.17E+03 | 15 | 0 | TNFSF9 | >100 | .034 |
| CLL phase and CLL-U | |||||||
| +2p25.3-p13.1 | 1.28E+04 | 7.40E+04 | 14 | 3 | REL, MYCN | >100 | .00432 |
| −8p23.3-p12 | 4.64E+04 | 3.45E+04 | 11 | 3 | >100 | .0302 | |
| −13q14.2-q14.3 | 5.05E+07 | 1.11E+03 | 32 | 53 | DLEU2/MIR15A/MIR16 | 12 | .034 |
| −15q15.1 | 4.01E+07 | 2.29E+03 | 14 | 3 | MGA | 55 | .0023 |
| −17p13.3-p11.2 | 5.26E+02 | 2.02E+04 | 32 | 6 | TP53 | >100 | <.00001 |
| −15q15.1 (homozygous loss) | 5.26E+02 | 2.02E+04 | 4 | 0.3 | MGA | 17 | .03025 |
| RS and de novo DLBCL | |||||||
| +1q32.1 | 2.02E+08 | 3.37E+03 | 15 | 28 | MDM4 | 57 | .0311 |
| −1p36.33-p36.31 | 6.17E+04 | 6.56E+03 | 15 | 28 | TNFRSF14, TP73 | >100 | .0196 |
| +2p16.1-p15 | 6.07E+07 | 2.38E+03 | 10 | 22 | REL | 19 | .0269 |
| +3q27-q29 | 1.88E+08 | 1.03E+04 | 13 | 28 | 81 | .0087 | |
| +5p15-q15 | 1.55E+04 | 9.55E+04 | 2 | 18 | >100 | .002 | |
| +6p25.3-p12.1 | 1.50E+05 | 5.38E+04 | 3 | 16 | >100 | .016 | |
| −6q23.3 | 1.37E+08 | 1.73E+03 | 9 | 38 | TNFAIP3 | 12 | .00003 |
| −6q16.3-q21 | 1.01E+08 | 6.50E+03 | 10 | 35 | PRDM1 | 17 | .00049 |
| +7 | 4.33E+04 | 1.59E+05 | 5 | 34 | >100 | .00002 | |
| −7q31.31-q36.3 | 1.18E+08 | 4.10E+04 | 13 | 3 | >100 | .017 | |
| +9q31.1-q34.11 | 1.08E+08 | 2.29E+04 | 4 | 12 | >100 | .023 | |
| −11q22.3 | 1.08E+08 | 4.97E+03 | 13 | 2 | ATM | 1 | .0046 |
| +12 | 1.00E+00 | 1.34E+08 | 27 | 17 | >100 | .046 | |
| −13q14.3 | 5.05E+07 | 1.10E+06 | 28 | 12 | DLEU2/MIR15A/MIR16 | 12 | .0075 |
| −14q24.1-q32.33 | 6.93E+07 | 3.69E+04 | 15 | 3 | TRAF3 | >100 | .0062 |
| −15q21.1-q21.1 | 4.11E+07 | 3.93E+03 | 7 | 31 | B2M, MGA | 78 | .0017 |
| +18 | 1.15E+04 | 7.80E+07 | 14 | 32 | BCL2, MALT1, NFATC1 | >100 | .011 |
| +20 | 6.13E+04 | 6.29E+04 | 0 | 13 | >100 | .0033 | |
| +21p11.2-q22.3 | 1.07E+07 | 3.74E+07 | 3 | 17 | >100 | .0090 |